Key points from article :
Rejuveron Life Sciences AG, a Swiss biotech focused on anti-ageing drugs, recently rebranded as Centenara Labs, marking a strategic shift toward greater visibility in the biotechnology sector. The company raised $75 million in funding last year to support its innovative approach using small molecules to regenerate endogenous stem cells, which are essential for treating age-related diseases.
Their most advanced program, EA-2353, is an early-stage clinical treatment for retinitis pigmentosa (RP), a degenerative eye condition that leads to vision loss. Recent preliminary data indicate positive safety results, giving hope to patients with RP, a condition with limited treatment options. Other companies in the race to combat RP include Beacon Therapeutics and Nanoscope Therapeutics, both exploring gene therapy-based solutions, with Beacon’s AGTC-501 in phase 2/3 and Nanoscope’s MCO-010 showing positive outcomes earlier this year.
Centenara’s CEO, Aksana Labokha, explained that the rebranding represents more than just a name change—it aligns with the company’s vision to develop regenerative therapies and age-related treatments that could potentially extend quality of life. Labokha highlighted that their new identity symbolizes this evolution, aiming to set Centenara apart in the crowded biotech landscape.
Despite strong interest in anti-ageing research, some companies have faced challenges. Unity Biotechnology, for example, halted its leading knee pain program in 2020 after a failed midstage trial, and AgeX Therapeutics struggled financially until it merged with Serina Therapeutics last year.
Centenara’s pivot and focus on regenerative medicine underscore their ambition in a field still grappling with the balance between promise and realistic breakthroughs, positioning them as a notable player in the ongoing effort to tackle age-related diseases and improve longevity.
